Literature DB >> 25672440

Delivery of fetus death with misoprostol in a pregnant woman with H7N9 avian influenza A virus pneumonia and ARDS.

Qiang Guo, Daguo Zhao, Fenglin Dong, Shenlan Liu, Youguo Chen, Jun Jin, Dustin R Fraidenburg, Jian-an Huang.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25672440      PMCID: PMC4210470          DOI: 10.1186/s13054-014-0589-7

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.
Pregnant women are susceptible to severe pneumonia and acute respiratory distress syndrome (ARDS) from influenza, which has been associated with increased fetal loss [1]. There is very little experience for the management of pregnant women with severe pneumonia and ARDS from avian influenza A (H7N9) virus, especially when complicated by intrauterine fetal death (IUFD). A 28-year-old pregnant woman was admitted to the hospital due to dyspnea, dry cough, and fever. The patient was at 26 weeks gestation. Infection with influenza A (H7N9) virus was confirmed from a tracheal aspirate sample using polymerase chain reaction assays. The fetus was monitored daily to check the heart rate and on admission the fetal heart rate was 140 beats/minute. The patient’s initial blood pressure was 70/45 mmHg, which was unresponsive to volume resuscitation. Norepinephrine was administrated to rescue septic shock and was required until day 11. On day 2, the beating of the fetal heart stopped as a result of severe, refractory hypoxemia (arterial oxygen pressure <50 mmHg, 24 hours). Echocardiography showed severe right ventricular dysfunction and severe left ventricular systolic dysfunction with decreased ejection fraction (26%). The renal function was slightly reduced with an elevated serum creatinine level (225 μmol/l). Despite the administration of oseltamivir, the patient’s condition progressed quickly. Thoracic imaging showing diffuse bilateral infiltrates along with evidence of impaired gas exchange led to the diagnosis of ARDS. Difficulties in oxygenation and a deteriorating medical condition resulted in incremental positive end-expiratory pressure titrations to a maximal value of 18 cmH2O and plateau pressure titrations to 40 cmH2O. During this course, the right ventricular systolic pressure was elevated to 52 mmHg on day 12. Severe pneumonia, septic shock, acute renal failure, acute heart failure, pulmonary hypertension, and ARDS complicated with IUFD posed a complex dilemma. On day 13, application of 200 μg misoprostol in the posterior fornix of the vagina was used to induce delivery with an induction-to-termination interval of 11.5 hours. No retained placenta or membranes were detected. Oxytocin augmentation (intramuscular injection, 10 mg) was given to prevent bleeding. In this complicated situation, misoprostol appears to be a safe, effective, and practical method for termination of IUFD [2]. Moreover, the heart function, refractory hypoxemia, pulmonary hypertension, and immunological function improved quickly on the day after the successful delivery (Table 1). Despite intensive medical therapies, catheter-related bloodstream infection and ARDS was complicated by severe pulmonary hypertension and the patient expired on hospital day 29.
Table 1

Blood oxygenation, heart function, myocardial enzyme spectrum, and blood cell count data before and after the fetal death delivery in a 28-year-old woman infected with influenza A (H7N9) virus

Day prior to fetal death delivery Day after fetal death delivery
Oxygenation and respiratory data
PaO2/FiO2 150187
Positive end-expiratory pressure (mmHg)109
Plateau pressure (mmHg)2825
Lung compliance (ml/cmH2O)43.461.5
Basic circulation data
Heart rate (beats/minute)135114
Mean arterial blood pressure (mmHg)10586
Vasoactive agentNoneNone
Echocardiographic data
Left ventricular ejection fraction (%)3368
Right ventricular systolic pressure (mmHg)5242
Left ventricular end-diastolic diameter (mm/m2)4143
Left ventricular end-systolic diameter (mm/m2)3529
Left atrial diameter (mm/m2)3627
Interventricular septal thickness (mm/m2)99
Left ventricular posterior wall thickness (mm/m2)87
Myocardial enzyme spectrum
Aspartate transaminase (u/l)6661
Creatine kinase (U/l)377122
Creatine kinase isomer-MB (u/l)2040
Lactate dehydrogenase (u/l)448411
Troponin (ng/ml)0.150.12
Blood cell counts
White blood cells (×109/l)26.727.4
Lymphocytes (×109/l)0.71.8
CD4+ T lymphocytes (%)9.042.4
CD8+ T lymphocytes (%)14.537.3
CD4+/CD8+ 0.621.14
CD3/CD19+ B lymphocytes (%)7.72.3
CD3CD56+ natural killer cells (%)4.818.9

The ratio of arterial oxygen pressure (PaO2) to the fractional concentration of inspired oxygen (FiO2) (PaO2/FiO2), pulmonary dynamic compliance, heart rate, left ventricular ejection fraction, right ventricular systolic pressure, left ventricular end-systolic diameter, creatine kinase isomer-MB, number of lymphocyte cells, CD4+ T-lymphocyte cell count, CD8+ T-lymphocyte cell count and CD3−CD56+ natural killer cell count were significantly improved after the fetal death delivery.

Blood oxygenation, heart function, myocardial enzyme spectrum, and blood cell count data before and after the fetal death delivery in a 28-year-old woman infected with influenza A (H7N9) virus The ratio of arterial oxygen pressure (PaO2) to the fractional concentration of inspired oxygen (FiO2) (PaO2/FiO2), pulmonary dynamic compliance, heart rate, left ventricular ejection fraction, right ventricular systolic pressure, left ventricular end-systolic diameter, creatine kinase isomer-MB, number of lymphocyte cells, CD4+ T-lymphocyte cell count, CD8+ T-lymphocyte cell count and CD3−CD56+ natural killer cell count were significantly improved after the fetal death delivery. Delivery of the fetus following IUFD using misoprostol in multiple organ failure patients was associated with improved immunological function, oxygenation, and heart function in this patient. We cannot help but consider that this may have provided more benefit early in the patient’s hospital course. Further studies may help identify the appropriate delivery time point and safety of this agent in IUFD women complicated with multiple organ failure.

Statement

The patient’s husband provided the written informed consent for the publication in the First Affiliated Hospital of Soochow University, and this would be available for review by the Editor-in-Chief.
  2 in total

1.  Risk of fetal death after pandemic influenza virus infection or vaccination.

Authors:  Siri E Håberg; Lill Trogstad; Nina Gunnes; Allen J Wilcox; Håkon K Gjessing; Sven Ove Samuelsen; Anders Skrondal; Inger Cappelen; Anders Engeland; Preben Aavitsland; Steinar Madsen; Ingebjørg Buajordet; Kari Furu; Per Nafstad; Stein Emil Vollset; Berit Feiring; Hanne Nøkleby; Per Magnus; Camilla Stoltenberg
Journal:  N Engl J Med       Date:  2013-01-16       Impact factor: 91.245

Review 2.  Misoprostol for induction of labour to terminate pregnancy in the second or third trimester for women with a fetal anomaly or after intrauterine fetal death.

Authors:  Jodie M Dodd; Caroline A Crowther
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14
  2 in total
  4 in total

Review 1.  The pandemic potential of avian influenza A(H7N9) virus: a review.

Authors:  W D Tanner; D J A Toth; A V Gundlapalli
Journal:  Epidemiol Infect       Date:  2015-07-24       Impact factor: 4.434

Review 2.  Hormonal Regulation of Physiology, Innate Immunity and Antibody Response to H1N1 Influenza Virus Infection During Pregnancy.

Authors:  Elizabeth Q Littauer; Ioanna Skountzou
Journal:  Front Immunol       Date:  2018-10-29       Impact factor: 7.561

3.  Severe Infection With Avian Influenza A Virus is Associated With Delayed Immune Recovery in Survivors.

Authors:  Jianing Chen; Guangying Cui; Chong Lu; Yulong Ding; Hainv Gao; Yixin Zhu; Yingfeng Wei; Lin Wang; Toshimitsu Uede; Lanjuan Li; Hongyan Diao
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

Review 4.  A review of vaccine effects on women in light of the COVID-19 pandemic.

Authors:  Wen-Han Chang
Journal:  Taiwan J Obstet Gynecol       Date:  2020-09-11       Impact factor: 1.705

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.